Research programme: phosphatase inhibitors - Amgen

Drug Profile

Research programme: phosphatase inhibitors - Amgen

Alternative Names: Research programme: WIP1 inhibitors - Amgen

Latest Information Update: 09 Sep 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amgen
  • Class Small molecules
  • Mechanism of Action Phosphoric monoester hydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 17 Aug 2004 Tularik has been acquired and merged into Amgen
  • 15 Aug 2003 Preclinical trials in Cancer in USA (unspecified route)
  • 15 Jun 2000 Preclinical development for Breast cancer in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top